Compound class:
Synthetic organic
Comment: The chemical structure for glovadalen was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a dopamine D1 receptor positive allosteric modulator (PAM). It is claimed in UCB Biopharma's patent WO2021001288A1 [1]. Exploration of UCB's declared pipeline suggests that glovadalen may be their clinical lead UCB0022, that is being developed for Parkinson's disease [2]. We will update this entry when the structure for UCB0022 and/or glovadalen is published.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
2-(3,5-dichloro-1-methylindazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(2-hydroxypropan-2-yl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone |
International Nonproprietary Names ![]() |
|
INN number | INN |
12927 | glovadalen |
Database Links ![]() |
|
CAS Registry No. | 2576359-31-2 (source: WHO INN record) |
GtoPdb PubChem SID | 491300014 |
PubChem CID | 155460962 |
Search Google for chemical match using the InChIKey | SVTDEVFVOSMAQQ-UONOGXRCSA-N |
Search Google for chemicals with the same backbone | SVTDEVFVOSMAQQ |
Search PubMed clinical trials | glovadalen |
Search PubMed titles | glovadalen |
Search PubMed titles/abstracts | glovadalen |
UniChem Compound Search for chemical match using the InChIKey | SVTDEVFVOSMAQQ-UONOGXRCSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | SVTDEVFVOSMAQQ-UONOGXRCSA-N |